Micronized Palmitoylethanolamide Ameliorates Methionine- and Choline-Deficient Diet-Induced Nonalcoholic Steatohepatitis via Inhibiting Inflammation and Restoring Autophagy
Laboratory studyOther animals
- Design
- Laboratory study
- Subjects
- C57BL/6 mice fed a methionine- and choline-deficient (MCD) diet to induce nonalcoholic steatohepatitis
- Dose used in the study
- Not stated in the abstract
- Duration
- Not stated in the abstract
- What was measured
- Liver function, hepatic pathology, lipid accumulation and fibrosis, ACC1, CD36, PPAR-alpha and AMPK phosphorylation, oxidative stress markers (GSH-px, SOD), inflammatory mediators, NLRP3 inflammasome activation, and autophagy markers.
What the authors reported
Palmitoylethanolamide improved liver function and reduced hepatic pathological changes, lipid accumulation and fibrosis in MCD-diet mice. It lowered ACC1 and CD36 expression, raised PPAR-alpha expression and AMPK phosphorylation, increased antioxidant enzyme activity, reduced inflammatory mediators and NLRP3 inflammasome activation, and reactivated impaired autophagy.
Limits of this study
A mouse model of diet-induced steatohepatitis; it cannot show effect in people with NASH. The authors declare no commercial or financial conflicts of interest.
Source
PubMed 34712137 · doi:10.3389/fphar.2021.744483
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.